News sentiment analysis powered by sentiment-insight.com
Trials of Promising Alzheimer's Vaccines Underway
Clinical trials are underway or completed for at least seven Alzheimer’s vaccines. Eisai and Biogen's newly launched Leqembi and Eli Lilly's donanemab are now under U.S. regulatory review.
FOCUS-Researchers return to Alzheimer's vaccines,... Clinical trials are underway or completed for at least seven Alzheimer's vaccines. Eisai and Biogen's newly launched Leqembi and Eli Lilly's donanemab are two such treatments.
Biogen cuts annual profit forecast as higher costs persist Biogen expects full-year adjusted profit per share in the range of $14.50 to $15.00 compared with $15 to $16 forecast previously. The company beat market expectations for profit in the third quarter.
Biogen cuts annual profit forecast on persistent higher costs Biogen cut its annual profit forecast below Wall Street expectations. Company had said in July it would cut about 1,000 jobs, or 11% of its workforce. Biogen is banking on the success of Leqembi and tuck-in deals to grow its revenue.
Biogen cuts annual profit forecast on persistent higher... Biogen expects full-year adjusted profit per share in the range of $14.50 to $15.00 compared with $15 to $16 forecast previously. The company had said in July it would cut about 1,000 jobs.
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 Biogen and Sage Therapeutics' oral pill to treat postpartum depression in adults is expected to cost U.S. wholesalers $15,900 for a full 14-day treatment. Drug, Zurzuvae, expected to be commercially available for adults with PPD in December.
Eisai expects Alzheimer's drug to rake in revenue of... Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024. Jefferies analyst Michael Yee estimated the drug to generate revenue of $28 million in 2023. U.S. partner Biogen will report third-quarter results on Nov. 8.
Biogen-Sage Therapeutics postpartum depression pill... Biogen and Sage Therapeutics' oral pill to treat postpartum depression expected to cost $15,900. The drug, Zurzuvae, is expected to be commercially available for adults with PPD in December.
US STOCKS-Wall St ends slightly higher after rally as... Wall St ends slightly higher after rally as Fed speakers, Treasury auctions eyed. Dish Network tumbles on Q3 revenue miss. Walt Disney, Instacart and Biogen are among major companies reporting earnings.
Walk to end Alzheimer's happening Oct. 28 Alzheimer's drug in injectable form could be the key for Biogen, Eisai. NASCAR Cup Series embarks up on a 36-race schedule in 2023. TikTok says the key to nailing the ‘old money’ aesthetic is this shiny hair oil.
Why Diagnosing Alzheimer’s Early Is So Important Eisai and Biogen, makers of the most recently approved drug, lecanemab (Leqembi), as well as Eli Lilly, maker of donanemab, reported on their latest studies. Lilly shared new data from its final phase of testing that showed patients’ ability to execute daily tasks improved.
U.S. agency removes coverage curb on PET scans for... U.S. agency removes coverage curb on PET scans for Alzheimer's patients. New drugs include Eisai and Biogen's Leqembi, and an experimental drug from Eli Lilly.
U.S. agency removes coverage curb on PET scans for Alzheimer's patients The new drugs include Eisai and Biogen's Leqembi, and an experimental drug from Eli Lilly known as donanemab. The change removes the once-per-lifetime limit on beta amyloid PET scans that restricted their use to clinical trials.
Japan approves Alzheimer treatment Leqembi by Eisai and Biogen Japan's health ministry approves Eisai's Alzheimer treatment Leqembi. The drug is co-developed with U.S.-based Biogen. It is the first treatment shown to slow progression of the disease for people in the earlier stages.
Reuters Health News Summary Novo Nordisk and Valo to research cardiometabolic treatments. Novartis confirms Sandoz spin-off for October 4, 2023. Japan approves Alzheimer treatment Leqembi by Eisai and Biogen.
Japanese health ministry panel recommends approval of Alzheimer's treatment Leqembi The expert panel's decision sets the stage for official approval of the drug. Leqembi was co-developed by Japan's Eisai and U.S.-based Biogen.
Japan health ministry panel recommends approval of Alzheimer's treatment Leqembi The expert panel's decision sets the stage for official approval of the drug. Leqembi is co-developed by Japan's Eisai and U.S.-based Biogen. The company expects to begin marketing the drug within about 60 days.
Few patients may qualify to get new Alzheimer’s drugs, study suggests Eisai's Leqembi and Biogen's Aduhelm are approved for older adults with mild cognitive impairment or early-stage Alzheimer's disease. Less than 1 in 10 patients at this point in the disease may be prescribed them. The estimate is based on how drugmakers studied the drugs in clinical trials.
FDA approves first pill for postpartum depression The drug, called zuranolone, is a once-a-day pill that will be branded as Zurzuvae by drugmakers Sage Therapeutics and Biogen.
Drugmakers say they’re adjusting their ‘thinking on price’ of first postpartum depression pill approved in the US Sage Therapeutics and Biogen are still ironing out how much zuranolone will cost. The companies’ goal is for the medication to be accessible to anyone with postpartum depression.
Sign Up
